Search

everythinglearnresearchcommunity

for

Search:↓

Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

Erlotinib can cause excessive eyelash growth.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

New probes were created to effectively measure specific enzymes involved in fat metabolism, which could help develop new drugs.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.

Adipose-derived stem cell-conditioned medium can reduce melanoma cell growth and spread.

Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Erlotinib can cause persistent excessive hair growth.

Topical calcitriol is safe for preventing hair loss during chemotherapy.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

Gefitinib therapy can cause unusual hair growth on the nose.

Early intervention and tailored management are crucial for skin side effects in cancer treatments.

Fosravuconazole effectively treated a woman's scalp infection without side effects.